John David Spence

Canadian physician

Uses your system voice; voice and rate in settings.

Q6228701Snapshot

≈ 5 min read

Names in other languages

  • astJohn David Spence
  • caJohn David Spence
  • DeutschJohn David Spence
  • EnglishJohn David Spence
  • EspañolJohn David Spence
  • FrançaisJohn David Spence
  • NederlandsJohn David Spence
  • slJohn David Spence

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

John David Spence (born November 10, 1944) was a Canadian medical doctor, medical researcher and Professor Emeritus at the University of Western Ontario. He was affiliated with the University of Western Ontario (where he taught Clinical Neurological Science) and the Robarts Research Institute, one of Canada's leading medical research organizations.

Early life

Before his retirement from clinical practice in July 2022, he was also affiliated with the London Health Sciences Centre's University Hospital (where he set up and ran stroke prevention clinics). He was a recognized expert in stroke prevention and stroke prevention research, with more than 600 peer-reviewed publications since 1970.

Reception

He delivered more than 600 lectures on stroke prevention in 42 countries. In 2015, he received the Research Excellence Award from the Canadian Society for Atherosclerosis, Thrombosis and Vascular Biology .

Career

In 2019, he was appointed a Member of the Order of Canada, and in 2020 he received the William Feinberg Award from the American Heart Association for excellence in clinical stroke research. Dr. Spence was the director of the [https://web.archive.org/web/20110125175043/http://www.robarts.ca/sparc/ Stroke Prevention & Atherosclerosis Research Centre (SPARC), a unit of the Robarts Research Institute.…

John David Spence (born November 10, 1944) was a Canadian medical doctor, medical researcher and Professor Emeritus at the University of Western Ontario. He was affiliated with the University of Western Ontario (where he taught Clinical Neurological Science) and the Robarts Research Institute, one of Canada's leading medical research organizations.

Before his retirement from clinical practice in July 2022, he was also affiliated with the London Health Sciences Centre's University Hospital (where he set up and ran stroke prevention clinics). He was a recognized expert in stroke prevention and stroke prevention research, with more than 600 peer-reviewed publications since 1970.

He delivered more than 600 lectures on stroke prevention in 42 countries. In 2015, he received the Research Excellence Award from the Canadian Society for Atherosclerosis, Thrombosis and Vascular Biology .

In 2019, he was appointed a Member of the Order of Canada, and in 2020 he received the William Feinberg Award from the American Heart Association for excellence in clinical stroke research. Dr. Spence was the director of the [https://web.archive.org/web/20110125175043/http://www.robarts.ca/sparc/ Stroke Prevention & Atherosclerosis Research Centre (SPARC), a unit of the Robarts Research Institute.

With Maria Dicicco, RVT, he pioneered the measurement of total plaque area (TPA) in a patient's carotid artery using ultrasound technology. The ability to measure TPA gives doctors the ability to treat, and measure the change in, the amount of plaque in a patient's arteries and has given researchers the ability to measure the effectiveness of new drug treatment therapies for stroke prevention in high-risk patients with narrowing of the carotid arteries, the process of "Treating Arteries" was associated with a >80% reduction in the 2-year risk of strokes and heart attacks.

Dr. Spence was recognized as "The Father of Total Plaque Area Measurement" and the importance of TPA measurement is that, in Dr Spence's words, "We can now treat arteries instead of just treating risk factors". Appropriate carotid endarterectomy: Showed in 2005 ( ) that with intensive medical therapy most patients with asymptomatic carotid stenosis cannot benefit from endarterectomy or stenting, and that the very small proportion (10%) who may benefit can be identified by microembolus detection on transcranial Doppler.

Showed in 2010 ( ) that the proportion who could benefit had declined with more intensive therapy to less than 5%. SPARC's work was confirmed in 2010 by an international multicenter study, the ACES study.

Dr. Spence led a study in the Canadian Atherosclerosis Imaging Network , on histological validation of imaging features of vulnerable plaque that will also serve to identify high-risk carotid plaques. Physiologically individualized therapy for resistant hypertension.

Reported in 2017 that in patients in three hypertension clinics in Africa, measuring plasma renin activity and aldosterone markedly improved blood pressure control, but permitting selection of the treatment that is appropriate to that patient, by identifying the physiological cause of the hypertension. Effects of the intestinal microbiome on atherosclerosis He reported with colleagues in 2018 that patients with carotid atherosclerosis not explained by traditional risk factors had higher blood levels of toxic metabolites produced by intestinal bacteria from foods such as red meat and egg yolk.

His group also found that blood levels of those toxic products are elevated with even moderate impairment of kidney function, such as seen in elderly patients. This has important implications for diet, and offers the possibility of an entirely new way of treating atherosclerosis: repopulation of the intestinal microbiome.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1376155988 under CC BY-SA 4.0; modifications have been made.

References

1 claim could not be tied to a specific sentence and is listed in the table below instead.